### SUNDAY 4 NOVEMBER

**10:00 am - 04:00 pm**  
**MMV Drug Combination Science Meeting**, Salons I-J Marriott downtown  
*Chair: Marcel Tanner, Swiss Tropical Institute*

### MONDAY 5 NOVEMBER

**08:00 am - 09:45 am**  
**Artemether/Lumefantrine Dispersible – ACTs Addressing Children’s Therapeutic Needs**, Symposium 2A, Salon A-B  
*Chair: Umberto D’Alessandro, Prince Leopold Institute of Tropical Medicine*

**10:15 am - 12:00 pm**  
**Scaling Up ACTs - the challenge of monitoring and ensuring safety, and developing an effective surveillance system in malaria endemic regions**, Symposium 19, Salon H  
*Chair: Charles Mgone, European and Developing Countries Clinical Trials*

**03:45 pm - 05:30 pm**  
**Medicines for Malaria Venture’s (MMV’s) Drug Discovery Portfolio**, Symposium 49, Liberty A-B  
*Chair: Winston Gutteridge, Medicines for Malaria Venture*

### TUESDAY 6 NOVEMBER

**05.00 pm - 06:45 pm**  
**Bridging the Access Gap: Countries Prepare to Ensure Prompt Access to New Antimalarials**, Symposium 100, Salon K-L  
*Co-chairs: Christopher Hentschel, Medicines for Malaria Venture; Richard W Steketee, MACEPA*

**05.00 pm - 06:45 pm**  
**Reinfection vs. Recrudescence in *P. falciparum* Malaria:**  
*From Molecular Analysis to Clinical Impact*, Symposium 93, Salon A-B  
*Chair: Dyanne Wirth, Harvard School of Public Health*

### THURSDAY 8 NOVEMBER

**08:00 am - 09:45 am**  
**Results of a randomised, multicentre, Phase II, dose-ranging clinical study to assess the safety and efficacy of fixed dose, orally administered pyronaridine and artesunate in adult patients**, Scientific session 159, Salon E  
*Presenter: Srivicha Krudsood, Mahidol University*

---

**Curing Malaria Together**

*Medicines for Malaria Venture*